Immunotherapy is a growing field in cancer research. A privileged tumor-associated antigen that has received much attention is N-glycolyl (NeuGc) GM3. This ganglioside is present in several types of cancer, but is almost undetectable in human healthy tissues. However, its non-hydroxylated variant, NeuAc GM3, is abundant in all mammals. Due to a deletion in the human gene encoding the key enzyme for synthesis of NeuGc, humans, in contrast to other mammals, cannot synthesize NeuGc GM3. Therefore the presence of this ganglioside in human cancer cells represents an enigma. It has been shown that hypoxic conditions trigger the expression of NeuGc gangliosides, which not only serve as attractive targets for cancer therapy, but also as diagnostic and prognostic tumor marker. Here, we confirm hypoxia-induced expression of the NeuGc GM3 ganglioside also in HeLa cells and reveal several candidate proteins, in particular GM3 synthase and subunit B of respiratory complex II, that may be involved in the generation of NeuGc GM3, by SILAC-based proteome analysis.
Introduction
Cancer immunotherapy promises a revolution in cancer therapy, and was consequently selected by Science as Breakthrough of the year 2013 (Couzin-Frankel 2013) . This type of therapy represents an entirely different approach to targeting and treating cancer compared to conventional therapies, such as radiation and chemotherapy. By selective targeting of tumor-specific antigens, treatment becomes more rational, with the potential for tailored personalized therapies.
One group of tumor-associated antigens with particularly attractive properties comprises sialic acid containing glycosphingolipids, or gangliosides [1, 2] . In mammalian tissues, the most abundant forms of sialic acids are N-acetyl neuraminic acid (NeuAc) and N-glycolyl neuraminic acid (NeuGc), however, in human healthy tissue, NeuGc is present only in minute amounts, suggestive of contamination, rather than active generation [3, 4] . The synthesis of this glycolipid requires an enzyme, cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH), which catalyzes the hydroxylation of NeuAc to yield NeuGc. This enzyme is non-functional in humans due to a 92-bp deletion in the gene encoding its active site [5] . However, when healthy cells transform into malignant cells, NeuGc is expressed [6] . The origin of this change in carbohydrate profile is unknown. Approaches to solve this mystery have so far focused mainly on diet incorporation of NeuGc from animal sources [4, [7] [8] [9] [10] . For example, it has recently been shown that Cmah knockout mice can incorporate NeuGc from dietary sources [11] . NeuGc uptake and recycling by the lysosomal transporter sialin is well studied [12] , and may be enhanced under hypoxic conditions [10] . Furthermore, an endogenous NeuGc-degrading pathway has recently been identified that produces N-acetylhexosamine metabolites, which may serve as precursors for the synthesis of NeuGc [13, 14] .
A NeuGc-containing ganglioside called NeuGc GM3 has attracted significant attention as tumor-associated antigen [6, 15, 16] . It is present on the surface of multiple types of cancers, such as breast cancer [17] , melanoma [18] result of adaptation to and survival within the environment limited in oxygen [23] . In addition, hypoxia-induced cancer progression can affect the expression of cell surface antigens, and indeed, the expression of NeuGc gangliosides has been shown to be triggered by hypoxic conditions [10] . Moreover, the aggressiveness of tumors correlates with CMAH expression levels [22] , whereas in the brain, which is rich in oxygen, CMAH (or Cmah) gene and NeuGc expression are suppressed [24] . However, the cellular mechanism causing the hypoxia-induced expression of NeuGc GM3 is still unknown.
NeuGc was originally considered an oncofetal antigen, since it is present in fetal tissue, but repressed during adult life. Normal embryonic development occurs in an environment low in oxygen, and hypoxia therefore also represents an important aspect of developmental morphogenesis [25, 26] , promoting differentiation and proliferation [27, 28] . The fact that hypoxia promotes both tumor progression and embryonic development could suggest that alternative mechanisms to synthesize NeuGc gangliosides exist in humans, but that hypoxia is required to induce production. . CC-BY-NC 4.0 International license not peer-reviewed) is the author/funder. It is made available under a The copyright holder for this preprint (which was . http://dx.doi.org/10.1101/125617 doi: bioRxiv preprint first posted online Apr. 7, 2017;
Results and Discussion
Hypoxia-induced expression of NeuGc gangliosides has previously been observed in LS174T, Caco-2 and ZR-75-1 cells [10] . To probe if hypoxia also triggers increased expression of NeuGc GM3 in the HeLa P cell line, flow cytometry experiments were performed. For detection, we used the murine antibody 14F7, which specifically recognizes NeuGc GM3 and can discriminate it from the very similar NeuAc derivative [18, [33] [34] [35] . This antibody was earlier subjected to glycoarray screening by the Functional Glycomics Consortium (www.functionalglycomics.org), with negative results, even for the NeuGc GM3 trisaccharide (data not shown), indicating that it is indeed very specific and furthermore requires the ganglioside's sphingolipid part for antigen recognition. Since NeuGc GM3 is abundant in most mammalian tissues (except brain tissue), but deficient in healthy human adults [24, 36] , we cultivated the cells in human serum for 2-3 weeks before analysis. Figure 1 shows that hypoxic conditions indeed induced a three-fold increase in expression of NeuGc GM3 in HeLa cells, in support of the hypothesis that hypoxia is an important factor for the generation of this antigen. To confirm our results, we repeated the experiment using chicken serum. Chicken, like other birds (as well as humans, reptiles and platypus), are deficient in NeuGc [37] . We observed that hypoxia induced a similar two-fold increase in expression of NeuGc GM3 in chicken serum, as determined by FACS analysis with 14F7 ( Figure S1 ), whereas culturing in NeuGc-rich fetal bovine serum showed no such effect ( Figure S2 ), in keeping with the hypothesis that de novo NeuGc synthesis can be induced by hypoxia.
But how does hypoxia trigger the expression of NeuGc GM3? What are the cellular mechanisms involved, and is de novo synthesis required or could other factors be at play? It has been suggested that hypoxic culture induces the expression of sialin, a sialic acid transporter, leading to increased incorporation of NeuGc from the external environment [10] . Indeed, a recent study of aggressive melanoma showed that the amount of NeuGc GM3 depended on the external medium [22] . However, we did not observe an increased expression of NeuGc GM3 using media supplemented with fetal bovine serum, which contains NeuGc ( Figure S2 ). Sialin (SLC17A5) was not identified in our recent SILAC study, not even at below-significance levels, even though 26 other proteins from the SCL-family were detected, of which four were up-regulated [32] . One .
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We found, using SILAC, that GM3 synthase was up-regulated 1.5 fold (although with low statistical significance; p=0.11), which was confirmed by Western blot analysis ( Figure S3 ). This could contribute to the increased synthesis of both NeuAc and NeuGc GM3. However, since the human and chicken sera used in the experiments lack NeuGc, it is unlikely that GM3 synthase is the sole responsible for hypoxiainduced NeuGc GM3 expression, even though it may play an important role.
In the same study, we found an iron-sulfur [ Gangliosides can rearrange in the membrane and create "clusters" together with cholesterol (referred to as "lipid rafts"), forming more ordered regions of the membrane [38] [39] [40] . The density, presentation and organization of glycosphingolipids may affect antibody specificity [2, [41] [42] [43] [44] and it has been shown that some ganglioside antigens are not fully antigenic and thus fail to interact with antibodies when their density is below a threshold value [45] . Currently, we cannot exclude that the increased binding of the 14F7 antibody after hypoxia treatment is caused or enhanced by such membrane remodeling. Another possibility is the recycling of gangliosides from other compartments in the cell and transport to the cell surface, where antibody detection occurs.
Nevertheless, it is intriguing that GM3 synthase is strongly up-regulated under hypoxic conditions, suggesting that in vivo NeuGc GM3 synthesis might actually occur. This Rieske domain is yet to be investigated. Mitochondria are the major consumers of iron in the cell and hence the primary sites for the synthesis of iron-sulfur clusters [46] .
Since Fe/S clusters are required for viability and exist in all kingdoms of life, the loss of these components is lethal during early embryonic development, and mutations in genes encoding proteins with such functionalities may cause severe disease in humans [46, 47] . Similarly, Fe/S clusters may be important for survival and growth of cancer cells, by inducing NeuGc ganglioside synthesis.
Another interesting aspect of this study relates to cancer immunotherapy. The strong evidence for hypoxia causing tumor progression and its importance in therapy resistance makes hypoxia-regulated molecules valuable therapeutic targets. Antitumor antibodies that recognize or mimic such hypoxia markers, like 14F7 and 1E10 (racotumumab), may owe their promising clinical potential [48] [49] [50] [51] [52] [53] [54] [55] at least in part to their ability to home in on the tumor center or generate anti-idiotypic antibodies with this ability. Inside the tumor, where hypoxia rules, expression of the targets is greatest; hence antibody binding will be strongest. Initial binding to the tumor surface should hence trigger the antibody's walk to the tumor center, to treat it from its roots.
Antibodies recognizing hypoxia-rich regions of the tumor, especially with highly dynamic association-dissociation kinetics, should hence be highly attractive for cancer therapies, either stand-alone or as potential adjuvants.
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Materials and Methods

Cell cultivation
For hypoxic conditions, HeLa P cells were grown inside an InVivo2 400 incubator box (Ruskinn Technology, UK) where the oxygen level inside the box was set to 1%, while a standard CO 2 incubator was used normoxic conditions. Prior to treatment, the cells were cultivated in Dulbecco's modified Eagle's medium (DMEM), supplemented with NeuGc free 10% human or chicken serum (H4522-Sigma, C5405-Sigma) and 1% penicillin/streptomycin for two to three weeks in order to ensure that no NeuGc was available in the medium. The experiment was performed in three biological replicates.
Flow cytometry
After growing the cells for 72h in hypoxia or normoxia, they were trypsinized and thereafter washed twice with a solution containing 49 ml phosphate buffered saline 
Bioinformatic data analyses
Bioinformatics analysis was performed with STRING 9.1 (http://string.embl.de/) [56, 57] , on data acquired previously by NanoLC-LTQ Orbitrap mass spectrometry, as 
